Please Wait
Applying Filters...
menu
    • menu
    TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.

    Virtual Booth

    Contact Supplier

    Your reliable CDMO partner - agile, scalable, top-quality Small Molecule API & HPAPI solutions from concept to market

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-11-24

    Virtual Booth

    An Enquiry

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Emavusertib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Curis to Host Conference Call and Webcast on November 6, 2025
    Curis to Host Conference Call and Webcast on November 6, 2025

    30 Oct 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/curis-to-report-third-quarter-2025-financial-and-operating-results-and-host-conference-call-and-webcast-on-november-6-2025-302600252.html

    PR NEWSWIRE
    30 Oct 2025
    Share Share
    Curis Discloses Inducement Grants Per NASDAQ LR 5635(C)(4)
    Curis Discloses Inducement Grants Per NASDAQ LR 5635(C)(4)

    03 Oct 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/curis-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-302575015.html

    PR NEWSWIRE
    03 Oct 2025
    Share Share
    Curis to Present at Upcoming Healthcare Conferences in September
    Curis to Present at Upcoming Healthcare Conferences in September

    02 Sep 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/curis-to-present-at-upcoming-healthcare-conferences-in-september-302543939.html

    PR NEWSWIRE
    02 Sep 2025
    Share Share
    Curis Enters into Agreement for Emavusertib Combination Study in Melanoma
    Curis Enters into Agreement for Emavusertib Combination Study in Melanoma

    05 Dec 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/curis-enters-into-agreement-for-emavusertib--pembrolizumab-combination-study-in-melanoma-302005577.html

    PR NEWSWIRE
    05 Dec 2023
    Share Share
    FDA lifts partial hold on Curis' PhI/II leukemia study as biotech raises $15M 
    FDA lifts partial hold on Curis' PhI/II leukemia study as biotech raises $15M 

    07 Jul 2023

    // Paul Schloesser ENDPTS

    https://endpts.com/fda-lifts-partial-hold-on-curis-phi-ii-leukemia-study-as-biotech-raises-15m/

    Paul Schloesser ENDPTS
    07 Jul 2023
    Share Share
    FDA Lifts Partial Clinical Hold on TakeAim Leukemia Trial Emavusertib in AML/MDS
    FDA Lifts Partial Clinical Hold on TakeAim Leukemia Trial Emavusertib in AML/MDS

    07 Jul 2023

    // ONCLIVE

    https://www.onclive.com/view/fda-lifts-partial-clinical-hold-on-takeaim-leukemia-trial-of-emavusertib-in-aml-mds

    ONCLIVE
    07 Jul 2023
    Share Share